Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $13,600 | 6 | 59.5% |
| Unspecified | $7,788 | 7 | 34.1% |
| Food and Beverage | $839.42 | 20 | 3.7% |
| Travel and Lodging | $604.47 | 2 | 2.6% |
| Education | $29.00 | 1 | 0.1% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $12,858 | 8 | $0 (2021) |
| Genentech USA, Inc. | $4,864 | 4 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $2,910 | 2 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $1,300 | 2 | $0 (2018) |
| PFIZER INC. | $395.66 | 2 | $0 (2022) |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $180.60 | 2 | $0 (2018) |
| Boston Scientific Corporation | $179.55 | 8 | $0 (2024) |
| ABBVIE INC. | $42.33 | 2 | $0 (2022) |
| DUSA Pharmaceuticals, Inc. | $38.80 | 2 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $29.47 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $30.18 | 1 | Boston Scientific Corporation ($30.18) |
| 2022 | $3,366 | 9 | E.R. Squibb & Sons, L.L.C. ($2,910) |
| 2021 | $5,477 | 5 | Novartis Pharmaceuticals Corporation ($5,400) |
| 2020 | $14.62 | 1 | Boston Scientific Corporation ($14.62) |
| 2019 | $39.30 | 2 | Boston Scientific Corporation ($23.05) |
| 2018 | $7,837 | 10 | NOVARTIS PHARMACEUTICALS CORPORATION ($7,131) |
| 2017 | $6,097 | 8 | Genentech USA, Inc. ($4,864) |
All Payment Transactions
36 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/06/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $30.18 | General |
| Category: General - Vascular Intervention_PI | ||||||
| 12/17/2022 | Boston Scientific Corporation | WATCHMAN Access System (Device) | Food and Beverage | In-kind items and services | $31.17 | General |
| Category: WATCHMAN_IC | ||||||
| 11/25/2022 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,900.00 | General |
| 11/02/2022 | Boston Scientific Corporation | WATCHMAN Access System (Device) | Food and Beverage | In-kind items and services | $18.65 | General |
| Category: WATCHMAN_IC | ||||||
| 09/16/2022 | Boston Scientific Corporation | General - Metallic Stents (Device) | Food and Beverage | In-kind items and services | $19.60 | General |
| Category: General - Metallic Stents_PI | ||||||
| 09/02/2022 | PFIZER INC. | EUCRISA (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: CRISABOROLE CLINICAL PUBLICATION PROGRAM • Category: DERMATOLOGY | ||||||
| 08/12/2022 | Boston Scientific Corporation | WATCHMAN Access System (Device) | Food and Beverage | In-kind items and services | $23.21 | General |
| Category: WATCHMAN_IC | ||||||
| 05/02/2022 | Boston Scientific Corporation | WATCHMAN Access System (Device) | Food and Beverage | In-kind items and services | $19.07 | General |
| Category: WATCHMAN_IC | ||||||
| 03/30/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $14.62 | General |
| Category: IMMUNOLOGY | ||||||
| 03/25/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $9.95 | General |
| 11/19/2021 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Consulting Fee | Cash or cash equivalent | $2,880.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/06/2021 | SANOFI-AVENTIS U.S. LLC | — | Education | In-kind items and services | $29.00 | General |
| 08/07/2021 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $29.47 | General |
| Category: Immunology | ||||||
| 08/07/2021 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $18.66 | General |
| 07/17/2021 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Consulting Fee | Cash or cash equivalent | $2,520.00 | General |
| Category: IMMUNOLOGY | ||||||
| 02/10/2020 | Boston Scientific Corporation | GENERAL - ATHERECTOMY (Device) | Food and Beverage | In-kind items and services | $14.62 | General |
| Category: ATHERECTOMY | ||||||
| 11/25/2019 | DUSA Pharmaceuticals, Inc. | ODOMZO (Drug), BLU-U, LEVULAN KERASTICK | Food and Beverage | Cash or cash equivalent | $16.25 | General |
| Category: Oncology | ||||||
| 03/14/2019 | Boston Scientific Corporation | GENERAL VASCULAR INTERVENTION (Device) | Food and Beverage | In-kind items and services | $23.05 | General |
| Category: VASCULAR | ||||||
| 08/22/2018 | Ortho Dermatologics, a division of Bausch Health US, LLC | JUBLIA (Drug), ELIDEL, ONEXTON | Food and Beverage | In-kind items and services | $34.56 | General |
| Category: PODIATRY | ||||||
| 07/19/2018 | DUSA Pharmaceuticals, Inc. | Levulan Kerastick (aminolevulinic acid HCl) for Topical Solution, 20% (Drug), BLU-U Blue Light Photodynamic Therapy Illuminator Model 4170 | Food and Beverage | In-kind items and services | $22.55 | General |
| Category: Dermatology | ||||||
| 05/28/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | XOLAIR (Biological) | — | In-kind items and services | $837.88 | Research |
| Study: RESEARCH RELATED PUBLICATION SUPPORT • Category: RESPIRATORY | ||||||
| 05/15/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | XOLAIR (Biological) | — | In-kind items and services | $2,356.25 | Research |
| Study: RESEARCH RELATED PUBLICATION SUPPORT • Category: RESPIRATORY | ||||||
| 04/13/2018 | Merck Sharp & Dohme Corporation | MK-8931 (Drug) | Consulting Fee | Cash or cash equivalent | $487.50 | General |
| Category: NEUROSCIENCE | ||||||
| 03/23/2018 | Celgene Corporation | Otezla (Drug) | Food and Beverage | In-kind items and services | $14.88 | General |
| Category: Dermatology | ||||||
| 02/16/2018 | Ortho Dermatologics, a division of Bausch Health US, LLC | — | Food and Beverage | In-kind items and services | $146.04 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $7,458 | 6 |
| CRISABOROLE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 6 | 100 | 131 | $19,234 | $3,616 |
| 2021 | 9 | 728 | 1,043 | $179,855 | $59,816 |
| 2020 | 11 | 754 | 1,175 | $142,526 | $48,999 |
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 16 | 19 | $4,715 | $971.42 | 20.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 31 | 33 | $5,856 | $922.44 | 15.8% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 15 | 16 | $3,596 | $732.64 | 20.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 11 | 11 | $2,446 | $474.09 | 19.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 15 | 16 | $2,149 | $367.81 | 17.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 12 | 36 | $473.76 | $147.38 | 31.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 135 | 203 | $50,729 | $17,633 | 34.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 185 | 250 | $44,244 | $15,090 | 34.1% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 79 | 105 | $23,413 | $8,242 | 35.2% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 65 | 71 | $14,396 | $4,808 | 33.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 38 | 38 | $12,796 | $4,139 | 32.3% |
| 17000 | Destruction of skin growth | Office | 2021 | 89 | 106 | $13,862 | $3,951 | 28.5% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 66 | 66 | $14,712 | $3,803 | 25.8% |
| 11104 | Punch biopsy of single skin lesion | Office | 2021 | 12 | 13 | $3,320 | $1,219 | 36.7% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 59 | 191 | $2,385 | $931.38 | 39.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 159 | 209 | $31,446 | $11,280 | 35.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 117 | 139 | $30,352 | $10,491 | 34.6% |
| 17110 | Destruction of up to 14 skin growths | Office | 2020 | 70 | 82 | $18,186 | $6,609 | 36.3% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2020 | 80 | 80 | $15,928 | $5,681 | 35.7% |
| 17000 | Destruction of skin growth | Office | 2020 | 106 | 126 | $16,461 | $4,642 | 28.2% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 59 | 59 | $12,783 | $4,309 | 33.7% |
| 99202 | New patient office or other outpatient visit, typically 20 minutes | Office | 2020 | 43 | 43 | $6,565 | $2,001 | 30.5% |
| 17003 | Destruction of 2-14 skin growths | Office | 2020 | 79 | 393 | $4,622 | $1,743 | 37.7% |
| 11104 | Punch biopsy of single skin lesion | Office | 2020 | 11 | 12 | $2,999 | $1,011 | 33.7% |
| 11103 | Tangential biopsy of additional skin lesion | Office | 2020 | 17 | 18 | $1,912 | $762.27 | 39.9% |
About Dr. Michael Tharp, MD
Dr. Michael Tharp, MD is a Dermatology healthcare provider based in Brandon, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1699785295.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Tharp, MD has received a total of $22,861 in payments from pharmaceutical and medical device companies, with $30.18 received in 2024. These payments were reported across 36 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($13,600).
As a Medicare-enrolled provider, Tharp has provided services to 1,582 Medicare beneficiaries, totaling 2,349 services with total Medicare billing of $112,431. Data is available for 3 years (2020–2022), covering 26 distinct procedure/service records.
Practice Information
- Specialty Dermatology
- Location Brandon, FL
- Active Since 08/08/2006
- Last Updated 01/23/2024
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1699785295
Products in Payments
- XOLAIR (Biological) $7,458
- COSENTYX (Biological) $5,400
- Rituxan (Biological) $4,864
- MK-8931 (Drug) $1,300
- EUCRISA (Drug) $395.66
- WATCHMAN Access System (Device) $92.10
- JUBLIA (Drug) $34.56
- TREMFYA (Drug) $29.47
- Humira (Biological) $27.71
- GENERAL VASCULAR INTERVENTION (Device) $23.05
- Levulan Kerastick (aminolevulinic acid HCl) for Topical Solution, 20% (Drug) $22.55
- General - Metallic Stents (Device) $19.60
- ODOMZO (Drug) $16.25
- Otezla (Drug) $14.88
- GENERAL - ATHERECTOMY (Device) $14.62
- SKYRIZI (Biological) $14.62
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Brandon
Dr. Andres Tobon, Do, DO
Dermatology — Payments: $43,245
Dr. Stephen Lockwood, Md, MD
Dermatology — Payments: $20,254
Jerry Hedrick, Md, MD
Dermatology — Payments: $11,910
Dr. Sanjay Agarwal, Do, DO
Dermatology — Payments: $6,726
Michael Abrouk, Md, MD
Dermatology — Payments: $6,543
Mckenna Abercrombie Dewees, Do, DO
Dermatology — Payments: $3,222